Severe Deficiency of B Lymphocytes in Peripheral Blood from Multiple Myeloma Patients

Overview

Journal J Clin Invest

Specialty General Medicine

Date 1984 Oct 1

PMID 6332828

Citations 15

Authors

L M Pilarski

M J Mant

B A Ruether

A Belch

Affiliations

Soon will be listed here.

Abstract

A major problem in the assessment of circulating B lymphocytes in multiple myeloma is the extent to which cells with passively absorbed Ig contribute to the assay. We have analyzed peripheral blood B cell numbers in 51 patients in various treatment categories by using an assay that is not subject to artifacts involving cytophilic Ig. We have defined a B lymphocyte by three different criteria (a) expression of a high surface density of Ig (b) expression of a high density of HLA.DR and (c) expression of a marker exclusive to surface Ig+ B cells. By these criteria, normal individuals have an average of 6% B cells. In multiple myeloma patients, B cell levels in purified mononuclear cell preparations are severely reduced. Untreated patients and the majority of patients on intermittent chemotherapy have 20-600-fold fewer B cells than do normal donors (average = 0.3%). This decrease was even greater in whole blood of patients as compared with normal donors (100-1,000-fold fewer B cells). The number of B cells did not correlate with disease status or paraprotein concentration. We found no evidence to support the idea that B lymphocytes in patients include a substantial monoclonal subset.

Citing Articles

Peripheral regulatory T lymphocytes recirculating to the thymus suppress the development of their precursors.

Thiault N, Darrigues J, Adoue V, Gros M, Binet B, Perals C Nat Immunol. 2015; 16(6):628-34.

PMID: 25939024 DOI: 10.1038/ni.3150.

The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma.

Giannopoulos K, Kaminska W, Hus I, Dmoszynska A Br J Cancer. 2012; 106(3):546-52.

PMID: 22223085 PMC: 3273338. DOI: 10.1038/bjc.2011.575.

Multiple Myeloma Includes Phenotypically Defined Subsets of Clonotypic CD20+ B Cells that Persist During Treatment with Rituximab.

Pilarski L, Baigorri E, Mant M, Pilarski P, Adamson P, Zola H Clin Med Oncol. 2011; 2:275-87.

PMID: 21892289 PMC: 3161648. DOI: 10.4137/cmo.s615.

Production of interleukin 2 in multiple myeloma.

Commes T, Klein B, Jourdan M, Bataille R Clin Exp Immunol. 1986; 63(3):533-40.

PMID: 3486731 PMC: 1577538.

Delay and not deficiency in cap formation of peripheral blood B cells in patients with multiple myeloma.

Zhang X, Klein B, Duperray C, BROCHIER J, Bataille R J Clin Immunol. 1988; 8(4):244-9.

PMID: 3137244 DOI: 10.1007/BF00916552.

References

Sato I, Abo T, Onodera S, Kumagai K . Detection of monoclonal B lymphocytes in multiple myeloma by immunofluorescence tests of surface immunoglobulins. Scand J Haematol. 1978; 21(5):433-44. DOI: 10.1111/j.1600-0609.1978.tb00391.x. View

Waters C, Pilarski L, Wegmann T, Diener E . Tolerance induction during ontogeny. I. Presence of active suppression in mice rendered tolerant to human gamma-globulin in utero correlates with the breakdown of the tolerant state. J Exp Med. 1979; 149(5):1134-51. PMC: 2184860. DOI: 10.1084/jem.149.5.1134. View

Van Acker A, Conte F, Hulin N, Urbain J . Idiotypic studies on myeloma B cells. Eur J Cancer (1965). 1979; 15(5):627-35. DOI: 10.1016/0014-2964(79)90136-1. View

Kubagawa H, Vogler L, Capra J, CONRAD M, Lawton A, Cooper M . Studies on the clonal origin of multiple myeloma. Use of individually specific (idiotype) antibodies to trace the oncogenic event to its earliest point of expression in B-cell differentiation. J Exp Med. 1979; 150(4):792-807. PMC: 2185666. DOI: 10.1084/jem.150.4.792. View

Shimizu K, Murate T, KUNII A . Circulating immunoglobulin-secreting cells in patients with plasma cell dyscrasia. Blood. 1980; 55(4):590-4. View

Schedel I, Peest D, Stunkel K, Fricke M, Eckert G, Deicher H . Idiotype-bearing peripheral blood lymphocytes in human multiple myeloma and Waldenström's macroglobulinaemia. Scand J Immunol. 1980; 11(4):437-44. DOI: 10.1111/j.1365-3083.1980.tb00010.x. View

Pruzanski W, Gidon M, Roy A . Suppression of polyclonal immunoglobulins in multiple myeloma: relationship to the staging and other manifestations at diagnosis. Clin Immunol Immunopathol. 1980; 17(2):280-6. DOI: 10.1016/0090-1229(80)90097-5. View

Boccadoro M, Van Acker A, Pileri A, Urbain J . Idiotypic lymphocytes in human monoclonal gammopathies. Ann Immunol (Paris). 1981; 132C(1):9-19. DOI: 10.1016/0769-2625(81)90003-9. View

King M, Wells J . Cell-bound immunoglobulin on peripheral blood mononuclear cells of patients with myeloma. Clin Exp Immunol. 1981; 45(3):552-6. PMC: 1537403. View

10.

Bast E, Van Camp B, Reynaert P, Wiringa G, Ballieux R . Idiotypic peripheral blood lymphocytes in monoclonal gammopathy. Clin Exp Immunol. 1982; 47(3):677-82. PMC: 1536443. View

11.

Harris J, Alexanian R, Hersh E, Migliore P . Immune function in multiple myeloma: impaired responsiveness to keyhole limpet hemocyanin. Can Med Assoc J. 1971; 104(5):389-93. PMC: 1930886. View

12.

Lindstrom F, Hardy W, Eberle B, Williams Jr R . Multiple myeloma and benign monoclonal gammopathy: differentiation by immunofluorescence of lymphocytes. Ann Intern Med. 1973; 78(6):837-44. DOI: 10.7326/0003-4819-78-6-837. View

13.

UNANUE E, Karnovsky M . Redistribution and fate of Ig complexes on surface of B lymphocytes: functional implications and mechanisms. Transplant Rev. 1973; 14:184-210. DOI: 10.1111/j.1600-065x.1973.tb00107.x. View

14.

SELIGMANN M, PreudHomme J, Brouet J . B and T cell markers in human proliferative blood diseases and primary immunodeficiencies, with special reference to membrane bound immunoglobulins. Transplant Rev. 1973; 16:85-113. DOI: 10.1111/j.1600-065x.1973.tb00118.x. View

15.

Cohen H . Human lymphocyte surface immunoglobulin capping. Normal characteristics and anomalous behavior of chronic lymphocytic leukemic lymphocytes. J Clin Invest. 1975; 55(1):84-93. PMC: 301720. DOI: 10.1172/JCI107921. View

16.

Abdou N, Abdou N . The monoclonal nature of lymphocytes in multiple myeloma. Effects of therapy. Ann Intern Med. 1975; 83(1):42-5. DOI: 10.7326/0003-4819-83-1-42. View

17.

Kumagai K, Abo T, Sekizawa T, Sasaki M . Studies of surface immunoglobulins on human B lymphocytes. I. Dissociation of cell-bound immunoglobulins with acid pH or at 37 degrees C. J Immunol. 1975; 115(4):982-7. View

18.

Chen Y, Bhoopalam N, YAKULIS V, Heller P . Changes in lymphocyte surface immunoglobulins in myeloma and the effect of an RNA-containing plasma factor. Ann Intern Med. 1975; 83(5):625-31. DOI: 10.7326/0003-4819-83-5-625. View

19.

Holm G, Mellstedt H, Pettersson D, Biberfeld R . Idiotypic immunoglobulin structures on blood lymphocytes in human plasma cell myeloma. Immunol Rev. 1977; 34:139-64. DOI: 10.1111/j.1600-065x.1977.tb00371.x. View

20.

PreudHomme J, Klein M, Labaume S, SELIGMANN M . Idiotype-bearing and antigen-binding receptors produced by blood T lymphocytes in a case of human myeloma. Eur J Immunol. 1977; 7(12):840-6. DOI: 10.1002/eji.1830071204. View